Back to search results

A Study of PF-07275315 for Moderate to Severe COPD

This study is investigating PF-07275315, a potential new treatment for moderate to severe Chronic Obstructive Pulmonary Disease (COPD). COPD is a lung condition that makes breathing difficult. The study aims to understand how well PF-07275315 works and if it is safe. You might be able to join if you are 35 to 80 years old, have had moderate to severe COPD for at least 12 months, and have experienced at least two flare-ups (exacerbations) in the past year. All participants will receive either PF-07275315 or a placebo, which looks like the study medicine but contains no active drug. The study will measure improvements in breathing (FEV1) and how often flare-ups occur.

Study design
This is an interventional study with a planned enrollment of 1156 participants. Participants will receive either PF-07275315 at different doses or a placebo via subcutaneous (SC) injection.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track changes in breathing for 24 weeks and the rate of moderate or severe COPD flare-ups for 52 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07363694

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting
PHASE2Ages 35–80InterventionalTreatment
Pfizer
~1,156 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:PF-07275315 dose 1PF-07275315-dose 2PlaceboPF-07275315-dose 3

At a glance

Recruiting sites
88 of 103 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24
Measured over Baseline to Week 24
+1 more outcome measured

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease

Explore related trials

Chronic Obstructive Pulmonary Disease

Where it's being run

103 sites across 55 states
Florida12
Texas7
Taiwan7
Missouri5
California4
Michigan4
South Carolina4
Alabama3

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition).
Spirometry values (post-bronchodilator forced expiratory volume in 1 second \[FEV1\]/forced vital capacity \[FVC\] less than \[\<\] 70 percent (%) and post-bronchodilator FEV1 % predicted \<70%, but greater than equal to 30%).
Continuous treatment with standard of care triple therapy of LABA + LAMA + ICS for ≥ 6 months prior to Screening Visit 1 and at a stable dose for ≥3 months
Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.

Exclusion

Significant pulmonary disease other than COPD.
Requirement for continuous chronic treatment with oxygen at \>4.0 liters / minute by nasal cannula or equivalent.
Hypoxemia with a resting SpO2 \<88% while breathing ambient air (or on the participant's usual level of oxygen supplementation).
Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale.

What this trial measures

  • Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24Baseline to Week 24

    FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.

  • Phase 3 part: Annualized rate of moderate or severe ECOPDBaseline to Week 52

    Exacerbation of Chronic Obstructive Pulmonary Disease (ECOPD) are sudden worsening of respiratory symptoms that significantly worsen lung function and quality of life.